An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area

Zhongji Meng; Tongyu Wang; Li Chen; Xinhe Chen; Longti Li; Xueqin Qin; Hai Li; Jie Luo

doi:10.1101/2020.04.11.20061473

Article Information

doi

https://doi.org/10.1101/2020.04.11.20061473

History

April 17, 2020.

Article Versions

You are currently viewing Version 1 of this article (April 17, 2020 - 04:54).
View Version 2, the most recent version of this article.

The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

Zhongji Meng1,
Tongyu Wang2,
Li Chen1,
Xinhe Chen1,
Longti Li1,
Xueqin Qin1,
Hai Li2 and
Jie Luo1,*

¹Novel Coronavirus Pneumonia Prevention and Control Team, Taihe Hospital, Hubei University of Medicine. Shiyan, Hubei, China
²Department of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University. Shanghai, China

↵*Corresponding author Correspondence:
Jie Luo, Novel Coronavirus Pneumonia Prevention and Control Team, Taihe Hospital, Hubei University of Medicine. Shiyan, Hubei, 442000, China. Email: jie.luo{at}aliyun.com